Our services detect both novel and known variants, including all four main classes of genomic alterations, across >300 cancer-relevant genes in a single test.^1–7 We leverage next-generation sequencing (NGS) technology to examine regions of the tumour genome that other tests
miss.^{1–7,12,14–18} In the same test we also report microsatellite instability (MSI)* and tumour
mutational burden (TMB) or blood tumour mutational burden (bTMB)*
alongside a comprehensive set of genes: ^1–7

• MSI informs eligibility for immunotherapies.^19–23
• TMB and bTMB are exploratory genomic signatures that inform eligibility for immunotherapies independently of PD-L1 expression.^24–29
• Comprehensive genomic profiling is the only viable routine clinical option for measuring TMB and bTMB.^24–27  

A clear, in-depth report supports clinical decision-making by providing insights on the patient’s genomic profile as well as associated targeted therapies, immunotherapies and relevant clinical trials.^30,31 Approved therapies are ranked alphabetically within NCCN therapy categories (for additional information on the NCCN categories please refer to the NCCN Compendium® at www.nccn.org).

The validations of our comprehensive genomic profiling services are published in top-tier peer-reviewed journals, and the services are supported by a large and growing body of clinical evidence.^{1,3,5,7,32,33}

Our continuously growing genomic database currently includes over 400,000 genomic profiles in over 150 common and rare tumour subtypes, helping us to ensure our reporting of clinically-relevant genomic alterations is always up-to-date.³⁴